U.S. Hereditary Testing Market Size & Outlook, 2023-2030

The hereditary testing market in the United States is expected to reach a projected revenue of US$ 3,540.5 million by 2030. A compound annual growth rate of 8.1% is expected of the United States hereditary testing market from 2024 to 2030.
Revenue, 2023 (US$M)
$2,049.0
Forecast, 2030 (US$M)
$3,540.5
CAGR, 2024 - 2030
8.1%
Report Coverage
U.S.

U.S. hereditary testing market highlights

  • The U.S. hereditary testing market generated a revenue of USD 2,049.0 million in 2023 and is expected to reach USD 3,540.5 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
  • In terms of segment, hereditary non-cancer testing was the largest revenue generating disease type in 2023.
  • Hereditary Cancer Testing is the most lucrative disease type segment registering the fastest growth during the forecast period.


Hereditary testing market data book summary

Market revenue in 2023USD 2,049.0 million
Market revenue in 2030USD 3,540.5 million
Growth rate8.1% (CAGR from 2023 to 2030)
Largest segmentHereditary non-cancer testing
Fastest growing segmentHereditary Cancer Testing
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationHereditary Cancer Testing, Hereditary Non-cancer Testing
Key market players worldwideMyriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc


Other key industry trends

  • In terms of revenue, U.S. accounted for 28.2% of the global hereditary testing market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. hereditary testing market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 670.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hereditary Testing Market Scope

Hereditary testing market segmentation & scope
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Ovarian Cancer
Prostate Cancer
Stomach/Gastric Cancer
Melanoma
Sarcoma
Uterine Cancer
Pancreatic Cancer
Other Hereditary Cancer
Preimplantation Genetic Diagnosis & Screening
Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
Newborn Genetic Screening
Cardiac Diseases
Rare Diseases
Other Diseases
Cytogenetic
Biochemical
Molecular Testing

Hereditary Testing Market Companies

Name Profile # Employees HQ Website

U.S. hereditary testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.


Hereditary non-cancer testing was the largest segment with a revenue share of 84.76% in 2023. Horizon Databook has segmented the U.S. hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.


The U.S. is the largest market for hereditary testing, owing to easy access to newborn screening in this country. Newborn screening is one of the most successful public health programs in the U.S. According to Centers for Disease Control and Prevention (CDC), more than 4 million infants are screened, and thousands are treated early for disability and death every year in the U.S.

The participation rate of the U.S. population in newborn screening is around 95%. Early detection & diagnosis of disorders in newborns significantly improves the chances of healthy development and positive outcomes. However, overall growth in newborn screening is expected to decrease in the U.S. as compared to other countries, due to declining birthrate.

In 2018, there were 3,788,235 births, which represents a 2% decline in birthrate from 2017. Moreover, total fertility rate declined to 1,728 births per 1,000 women over their lifetimes, which represented a 2% decline from 2017.

Reasons to subscribe to U.S. hereditary testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. hereditary testing market databook

  • Our clientele includes a mix of hereditary testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into U.S. hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. hereditary testing market size, by disease type, 2018-2030 (US$M)

U.S. Hereditary Testing Market Share, 2023 & 2030 (US$M)

U.S. hereditary testing market size, by disease type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more